Initial Statement of Beneficial Ownership (3)
June 07 2021 - 06:44AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP
OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * RASTER INVESTMENTS,
Inc |
2. Date of Event Requiring Statement
(MM/DD/YYYY)
5/28/2021
|
3. Issuer Name and Ticker or Trading
Symbol Immune Therapeutics, Inc. [IMUN] |
(Last)
(First)
(Middle)
2384 ORCHARD CREST BLVD |
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
_____ Officer (give title
below) ___X___
Other (specify below)
/ Member of 10% owner group |
(Street)
MANASQUAN,, NJ 08736
(City)
(State)
(Zip)
|
5. If Amendment, Date Original
Filed(MM/DD/YYYY)
|
6. Individual or Joint/Group
Filing(Check Applicable
Line)_X_ Form filed by One Reporting
Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially
Owned
|
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Common Stock |
5650 (1) |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying
Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative
Security |
5. Ownership Form of Derivative Security: Direct (D)
or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Warrants (Right to Buy) |
12/31/2018 |
12/30/2023 |
Common Stock |
12000 |
$5.00 |
D |
|
Warrants (Right to Buy) |
5/31/2019 |
5/29/2024 |
Common Stock |
8000 |
$5.00 |
D |
|
Explanation of
Responses: |
(1) |
According to the Annual
Report on Form 10-K filed on April 15, 2021 (the "Form 10-K") by
the issuer, Immune Therapeutics, Inc. (the "Company"), a reverse
stock split of the Company's issued and outstanding, but not
authorized, common stock at a ratio of 1,000-to-1 (the "Reverse
Split") was approved by the Company's shareholders. The Reverse
Split is currently pending approval by the Financial Industry
Regulatory Authority, Inc. The information contained in the Form
10-K relating to the shares of Common Stock outstanding and
beneficially owned is based on the implementation of the Reverse
Split. The information presented herein is likewise based on the
implementation of the Reverse Split. The beneficial ownership
information presented in this Form 3 is otherwise based on the
beneficial ownership of the Reporting Persons as of the date of the
event requiring filing of this Form 3. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
RASTER INVESTMENTS, Inc
2384 ORCHARD CREST BLVD
MANASQUAN,, NJ 08736 |
|
|
|
Member of 10% owner group |
Signatures
|
/s/ Raster Investments, Inc.; By Marie Elena
Teraskiewicz, Director |
|
5/28/2021 |
**Signature of
Reporting Person |
Date |
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2022 to May 2022
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From May 2021 to May 2022